BACKGROUND: Diagnosing obstructive coronary artery disease (CAD) in at-risk patients can be challenging and typically requires both noninvasive imaging methods and coronary angiography, the gold standard. Previous studies have suggested that peripheral blood gene expression can indicate the presence of CAD. OBJECTIVE: To validate a previously developed 23-gene, expression-based classification test for diagnosis of obstructive CAD in nondiabetic patients. DESIGN: Multicenter prospective trial with blood samples obtained before coronary angiography. (ClinicalTrials.gov registration number: NCT00500617) SETTING: 39 centers in the United States. PATIENTS: An independent validation cohort of 526 nondiabetic patients with a clinical indication for coronary angiography. MEASUREMENTS: Receiver-operating characteristic (ROC) analysis of classifier score measured by real-time polymerase chain reaction, additivity to clinical factors, and reclassification of patient disease likelihood versus disease status defined by quantitative coronary angiography. Obstructive CAD was defined as 50% or greater stenosis in 1 or more major coronary arteries by quantitative coronary angiography. RESULTS: The area under the ROC curve (AUC) was 0.70 ± 0.02 (P < 0.001); the test added to clinical variables (Diamond-Forrester method) (AUC, 0.72 with the test vs. 0.66 without; P = 0.003) and added somewhat to an expanded clinical model (AUC, 0.745 with the test vs. 0.732 without; P = 0.089). The test improved net reclassification over both the Diamond-Forrester method and the expanded clinical model (P < 0.001). At a score threshold that corresponded to a 20% likelihood of obstructive CAD (14.75), the sensitivity and specificity were 85% and 43% (yielding a negative predictive value of 83% and a positive predictive value of 46%), with 33% of patient scores below this threshold. LIMITATION: Patients with chronic inflammatory disorders, elevated levels of leukocytes or cardiac protein markers, or diabetes were excluded. CONCLUSION: A noninvasive whole-blood test based on gene expression and demographic characteristics may be useful for assessing obstructive CAD in nondiabetic patients without known CAD. PRIMARY FUNDING SOURCE: CardioDx.
BACKGROUND: Diagnosing obstructive coronary artery disease (CAD) in at-risk patients can be challenging and typically requires both noninvasive imaging methods and coronary angiography, the gold standard. Previous studies have suggested that peripheral blood gene expression can indicate the presence of CAD. OBJECTIVE: To validate a previously developed 23-gene, expression-based classification test for diagnosis of obstructive CAD in nondiabeticpatients. DESIGN: Multicenter prospective trial with blood samples obtained before coronary angiography. (ClinicalTrials.gov registration number: NCT00500617) SETTING: 39 centers in the United States. PATIENTS: An independent validation cohort of 526 nondiabeticpatients with a clinical indication for coronary angiography. MEASUREMENTS: Receiver-operating characteristic (ROC) analysis of classifier score measured by real-time polymerase chain reaction, additivity to clinical factors, and reclassification of patient disease likelihood versus disease status defined by quantitative coronary angiography. Obstructive CAD was defined as 50% or greater stenosis in 1 or more major coronary arteries by quantitative coronary angiography. RESULTS: The area under the ROC curve (AUC) was 0.70 ± 0.02 (P < 0.001); the test added to clinical variables (Diamond-Forrester method) (AUC, 0.72 with the test vs. 0.66 without; P = 0.003) and added somewhat to an expanded clinical model (AUC, 0.745 with the test vs. 0.732 without; P = 0.089). The test improved net reclassification over both the Diamond-Forrester method and the expanded clinical model (P < 0.001). At a score threshold that corresponded to a 20% likelihood of obstructive CAD (14.75), the sensitivity and specificity were 85% and 43% (yielding a negative predictive value of 83% and a positive predictive value of 46%), with 33% of patient scores below this threshold. LIMITATION: Patients with chronic inflammatory disorders, elevated levels of leukocytes or cardiac protein markers, or diabetes were excluded. CONCLUSION: A noninvasive whole-blood test based on gene expression and demographic characteristics may be useful for assessing obstructive CAD in nondiabeticpatients without known CAD. PRIMARY FUNDING SOURCE: CardioDx.
Authors: B R Chaitman; M G Bourassa; K Davis; W J Rogers; D H Tyras; R Berger; J W Kennedy; L Fisher; M P Judkins; M B Mock; T Killip Journal: Circulation Date: 1981-08 Impact factor: 29.690
Authors: Raymond J Gibbons; Jonathan Abrams; Kanu Chatterjee; Jennifer Daley; Prakash C Deedwania; John S Douglas; T Bruce Ferguson; Stephan D Fihn; Theodore D Fraker; Julius M Gardin; Robert A O'Rourke; Richard C Pasternak; Sankey V Williams Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Allen P Burke; Frank D Kolodgie; Arthur Zieske; David R Fowler; Deena K Weber; P Jacob Varghese; Andrew Farb; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2004-05-13 Impact factor: 8.311
Authors: J S Rana; S M Boekholdt; P M Ridker; J W Jukema; R Luben; S A Bingham; N E Day; N J Wareham; J J P Kastelein; K-T Khaw Journal: J Intern Med Date: 2007-10-01 Impact factor: 8.989
Authors: James A Wingrove; Susan E Daniels; Amy J Sehnert; Whittemore Tingley; Michael R Elashoff; Steven Rosenberg; Lutz Buellesfeld; Eberhard Grube; L Kristin Newby; Geoffrey S Ginsburg; William E Kraus Journal: Circ Cardiovasc Genet Date: 2008-10
Authors: Peter W F Wilson; Michael Pencina; Paul Jacques; Jacob Selhub; Ralph D'Agostino; Christopher J O'Donnell Journal: Circ Cardiovasc Qual Outcomes Date: 2008-11-09
Authors: William E Kraus; Christopher B Granger; Michael H Sketch; Mark P Donahue; Geoffrey S Ginsburg; Elizabeth R Hauser; Carol Haynes; L Kristin Newby; Melissa Hurdle; Z Elaine Dowdy; Svati H Shah Journal: J Cardiovasc Transl Res Date: 2015-08-14 Impact factor: 4.132
Authors: Parag H Joshi; Sarah Rinehart; Gustavo Vazquez; Zhen Qian; Abhinav Sharma; Hunt Anderson; Laura Murrieta; Nancy Flockhart; Dimitri Karmpaliotis; Anna Kalynych; Bela Asztalos; Michael R Elashoff; John Blanchard; Steven Rosenberg; Charles Brown; Szilard Voros Journal: Cardiovasc Diagn Ther Date: 2013-03
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Roby Joehanes; Saixia Ying; Tianxiao Huan; Andrew D Johnson; Nalini Raghavachari; Richard Wang; Poching Liu; Kimberly A Woodhouse; Shurjo K Sen; Kahraman Tanriverdi; Paul Courchesne; Jane E Freedman; Christopher J O'Donnell; Daniel Levy; Peter J Munson Journal: Arterioscler Thromb Vasc Biol Date: 2013-03-28 Impact factor: 8.311